Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study will determine the efficacy, safety, and tolerability of a 40 milligrams (mg)
once-daily (QD) dose of LY2940094 for 8 weeks in participants with MDD.
Phase:
Phase 2
Details
Lead Sponsor:
BlackThorn Therapeutics, Inc. Eli Lilly and Company